-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $17

Benzinga·03/18/2026 10:23:55
Listen to the news
Truist Securities analyst Danielle Brill initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $17.